cmAngio® vs uOmnispace.MI
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your primary objective is to opportunistically screen for cardiovascular risk in women by automatically detecting Breast Arterial Calcifications (BAC) on existing mammograms. This AI-powered solution seamlessly integrates into your mammography workflow, providing valuable insights for early risk assessment without requiring additional radiation or procedures.
View cmAngio® →Choose uOmnispace.MI if…
Choose uOmnispace.MI if your clinical practice requires a comprehensive, multi-modality imaging workstation for advanced 2D and 3D visualization, AI-enhanced segmentation, and quantitative analysis across PET, CT, MR, and SPECT images. This tool is ideal for detailed diagnostic and treatment planning workflows in specialties such as oncology, neurology, and cardiology, offering features like lesion segmentation and dynamic PET data analysis.
View uOmnispace.MI →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | uOmnispace.MI |
|---|---|---|
| Pricing | Paid, out-of-pocket | Unknown |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Unknown |
| FDA Status | Cleared AI-estimated | Unknown |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®Tool A emphasizes ease of integration and a focused workflow, with claims of 'quick and easy installation (less than an hour)' and compatibility with 'any DICOM-compliant viewer'. While Tool B offers a broader feature set, Tool A's specific design for a single, high-impact task suggests a smoother and more straightforward user experience for its intended purpose.
Clinical Value
cmAngio®Tool A offers a highly specific and potentially transformative clinical value by detecting Breast Arterial Calcifications (BAC) on routine mammograms for cardiovascular risk assessment. This leverages existing imaging data for a novel purpose, addressing a significant unmet need in women's health without additional procedures or radiation. Tool B provides broad utility across multiple modalities and specialties but in more general terms of supporting workflows and analysis.
Pricing & Value
cmAngio®Both tools have opaque pricing, requiring direct vendor contact. However, Tool A explicitly mentions 'limited-time offers for no-cost implementation and service' which, if available, would provide a clear and significant value advantage to potential customers.
Enterprise Readiness
uOmnispace.MITool B demonstrates superior enterprise readiness by explicitly confirming a Business Associate Agreement (BAA) and offering versatile deployment options including SaaS, on-premise, and hybrid models. This flexibility accommodates diverse IT infrastructures and security policies. Tool A's BAA status requires contacting the vendor, and its deployment is inferred as cloud-based, offering less stated adaptability.
Innovation
cmAngio®Tool A exhibits greater innovation by pioneering the use of AI to detect Breast Arterial Calcifications (BAC) on standard mammograms, repurposing existing data for cardiovascular risk assessment. This represents a novel application of AI to extract new, high-impact clinical insights from routine imaging. While Tool B offers advanced AI-enhanced segmentation, this is a more established application within medical imaging software.
Support & Docs
uOmnispace.MITool B appears to have a more comprehensive and explicitly stated support and documentation framework, including mentions of a 'System Operator Manual', 'UIH training and customer service engineers', a 'service training center', and '4DM Support, Maintenance, Training'. Tool A mentions an 'Operator's Manual' but provides less detail on its overall support infrastructure.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | uOmnispace.MI |
|---|---|---|
| Tool Name | cmAngiou00ae | uOmnispace.MI |
| Company | CureMetrix | Shanghai United Imaging Healthcare Co. |
| Primary Function | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | Advanced medical imaging software that provides comprehensive 2D and 3D viewing, AI-enhanced segmentation, and analysis tools for PET, CT, MR, and SPECT images, supporting clinical workflows in oncology, neurology, and cardiology. |
| Key Features (Summary) | AI-based detection of Breast Arterial Calcifications (BAC) on FFDM and DBT, visualization of BAC location, compatible with any DICOM-compliant viewer, adjustable operating point, quick and easy installation, cybersecurity. | 2D and 3D medical image viewing, annotation and measurement tools, manual and automatic segmentation (including AI-based rib extraction), support for DICOM images across CT, MRI, PET, SPECT modalities, remote multi-user access, image registration, quantitative analysis, and fusion imaging, dynamic PET data analysis. |
| Supported Specialties | Cardiology, Obstetrics & Gynecology, Radiology | Nuclear Medicine, Oncology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and uOmnispace.MI.